Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock. D. Boral Capital’s price target suggests a potential upside of 409.41% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Monday, November 4th.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $9.03 on Monday. The company has a 50 day simple moving average of $6.46 and a two-hundred day simple moving average of $5.58. The firm has a market cap of $765.71 million, a PE ratio of -18.06 and a beta of 0.60. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $10.45.

Institutional Trading of Anavex Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of AVXL. Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares during the period. Virtu Financial LLC boosted its holdings in Anavex Life Sciences by 87.5% during the 1st quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 18,954 shares during the period. Nwam LLC bought a new position in Anavex Life Sciences during the 3rd quarter worth approximately $5,172,000. Deerfield Management Company L.P. Series C purchased a new position in Anavex Life Sciences in the 2nd quarter worth approximately $346,000. Finally, Vanguard Group Inc. lifted its position in Anavex Life Sciences by 1.2% in the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after purchasing an additional 54,034 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.